Andrew Hopkins, Chief Executive at Exscientia to Discuss the Role of Artificial Intelligence in Small Molecule Drug Discovery

SMi reports: Andrew Hopkins, Chief Executive at Exscientia to discuss the role of Artificial Intelligence in small molecule drug discovery at SMi’s Drug Discovery conference in March 2018. [PR.com]

Pharmaceutical Stocks

[stock-ticker]

© 2018 Drugs News All rights reserved.       Privacy Policy       Contact Us